Call Our HELPLINE: 1-800-4PD-INFO (473-4636)


Nursing Solutions: PD Medication Adherence Challenges

Moderated by: Gwyn M. Vernon, M.S.N., R.N., C.R.N.P., Co-Founder and National Director of The Edmond J. Safra Visiting Nurse Faculty Program at Parkinson's Foundation

Led by: Ju Young Shin, Ph.D., A.P.R.N., A.N.P.-C., Assistant Professor of Nursing at the University of Delaware, Edie Simpson, R.N., C.N.R.N., EJS-VNF Host Coordinator, Muhammad Ali Parkinson's Center; Joan Gardner, R.N., B.S.N., Clinical Supervisor, Struthers Parkinson's Center, Park Nicollet Health Services

Learning Objectives:

Tips for Daily Living: Preparing for Summer with Parkinson’s Disease

Tuesday, June 20, 2017
Annie Wallis, MSW, LSW

Does summer have you thinking about traveling somewhere new or enjoying the great outdoors? Follow these tips on Parkinson’s disease (PD) and travel, sun safety and heat exhaustion:

Travel Hacks

Vacations are a big part of living well. Many people choose to travel during summer, but with Parkinson’s there are some extra things to consider before hitting the road. These tips can help you stay safe while you travel:

What's Hot in PD? Everything a Parkinson’s Patient Needs to Know about Safinamide (Xadago): Should You Switch?

Monday, April 3, 2017
Dr. Michael S. Okun

Safinamide (Xadago) was approved by the Food and Drug Administration (FDA) for treatment of Parkinson’s disease (PD) medication fluctuations. Safinamide is a pill that when absorbed in the bloodstream travels to the brain and affects dopaminergic and non-dopaminergic systems.

What's Hot in PD?: As a New Drug Gains FDA Approval for Parkinson’s Disease Psychosis (Nuplazid), Should We Fear Using it?

Friday, April 1, 2016
Dr. Michael S. Okun

This week the FDA approved the drug Pimavanserin (Nuplazid) for the treatment of Parkinson’s disease psychosis. There has been a critical, unmet need for development of better drugs to address hallucinations and psychosis in the setting of Parkinson's disease. We have learned over many years that typical high potency neuroleptic antipsychotic drugs (e.g.


mail icon

Subscribe to get the latest news on treatments, research and other updates.